Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market Perform on Tuesday, boosting sales ...

Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

Since then, we have seen tavapadon deliver positive phase 3 results in Parkinson's disease patients, and while I am not too ...

The deal will include Aliada's lead investigational product, ALIA-1758 ... accelerating the development of new therapies for neurological disorders. AbbVie R&D executive vice-president and ...

reflecting confidence in its key immunology products, Skyrizi and Rinvoq, which are performing well in the market. Additionally, AbbVie’s management has reiterated their positive outlook for ...

One was to be a diversified medical products company – Abbott – and the other, a new researched-based global biopharmaceutical company – AbbVie. In January 2013, AbbVie was formed.

When evaluating AbbVie alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise: AbbVie holds a middle position in terms of the debt-to-equity ratio compared to ...